GlassScriptPhysician profile
Rafael Ruggieri
NPI 1932335130
$9,189.75
in general payments reported to CMS, 2019-2025
28 companies · $917 in 2025
The $917 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,664 · 2020: $584 · 2021: $397 · 2022: $1,317 · 2023: $690 · 2024: $1,620 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,163 · Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,163.36 |
| Food and Beverage | $1,064.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,749.13 | 2019-2023 | Da Vinci Surgical System |
| Globus Medical, INC. | $1,385.42 | 2021-2023 | Mars Anterior Retractor |
| Davol INC. | $899.75 | 2019-2025 | Phasix Mesh |
| Zimmer Biomet Holdings, INC. | $755.56 | 2024 | Advantagerib, Ribfix Blu Advantage |
| Stryker Corporation | $575.51 | 2024 | Lifepak 35 |
| Integra Lifesciences Corporation | $392.22 | 2020-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Smith+Nephew, INC. | $357.95 | 2019-2025 | Stravix Pl |
| Organogenesis INC. | $161.19 | 2019-2024 | Puraply |
| Tela Bio, INC. | $126.77 | 2019 | |
| Tactile Systems Technology INC | $102.74 | 2019-2025 | Nimbl, Flexitouch Plus |
| Ethicon US, LLC | $80.09 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.61 | 2022-2023 | Gattex |
| Csl Behring | $52.90 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $52.60 | 2025 | |
| Shire North American Group INC | $51.66 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $43.89 | 2021-2023 | Exparel |
| Tei Biosciences INC | $41.63 | 2019 | |
| Misonix INC | $41.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.03 | 2019 | |
| Kerecis Limited | $36.82 | 2022 | |
| Edwards Lifesciences Corporation | $35.69 | 2021 | |
| Impedimed, INC. | $34.23 | 2025 | |
| Kci USA, INC. | $26.37 | 2023 | Prevena Restor Bellaform, Abthera Advance, V.A.C. Veraflo Cleanse Choice |
| Braintree Laboratories, INC. | $23.75 | 2023 | Sutab |
| Bioptics, INC. | $19.78 | 2020 | |
| Heron Therapeutics, INC. | $18.22 | 2022 | |
| Solventum Corporation | $17.18 | 2025 | V.A.C.Ulta, Abthera, Prevena |
| Medtronic USA, INC. | $14.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Ruggieri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.